Premier Research, a clinical research company, has named Cassandra Matney, MD as its new senior medical director, it was reported on Monday.
Matney has experience in both solid and haemato-oncology tumours. Her therapeutic work in haematology and oncology includes prostate cancer, acute myeloid leukaemia, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndromes, B-cell malignancies, urothelial/bladder cancer, gastric/gastroesophageal cancer, and graft versus host disease.
Most recently, Matney managed medical affairs positions at Astellas Pharmaceuticals Global Development Inc, Janssen Oncology (a pharmaceutical company of Johnson & Johnson), and Incyte Corporation. She has also served as CRO and has site experience working at both Covance and academic centre Meharry Medical College, respectively.
Matney holds a medical degree at the Universidad Autonoma de Guadalajara and New York Medical College, and a Bachelor of Science degree from Illinois State University. She is certified by the Educational Commission for Foreign Medical Graduates.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval